Abstract
While the use of incretins, including GLP-1 receptor agonists and PDD-IV inhibitors, is well established in the treatment of type 2 diabetes, many other aspects of these agents are yet to be discovered and utilized for their potential clinical benefit. These include the potential role of GLP-1 receptor agonists in the induction of weight loss, blood pressure reduction, anti-inflammatory and nephro- and cardio-protective actions. Their potential benefit in type 1 diabetes is also being investigated. This review will attempt to comprehensively describe novel discoveries in the field of incretin pathophysiology and pharmacology beyond their classical role in the treatment of type 2 diabetes.
| Original language | English |
|---|---|
| Pages (from-to) | 59-67 |
| Number of pages | 9 |
| Journal | Diabetes, Obesity and Metabolism |
| Volume | 20 |
| DOIs | |
| State | Published - Feb 2018 |
Keywords
- cardiovascular disease
- diabetic nephropathy
- incretins
- type 1 diabetes
- weight control
Fingerprint
Dive into the research topics of 'Incretins: Beyond type 2 diabetes'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver